Campbell & CO Investment Adviser LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,240 shares of the medical research company’s stock, valued at approximately $628,000.

A number of other institutional investors also recently modified their holdings of BIO. Royal Bank of Canada increased its stake in Bio-Rad Laboratories by 25.2% during the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock valued at $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 45.6% during the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after buying an additional 32,874 shares during the last quarter. Empowered Funds LLC increased its position in shares of Bio-Rad Laboratories by 14.8% during the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after acquiring an additional 199 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Bio-Rad Laboratories by 95.3% in the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after acquiring an additional 18,239 shares during the last quarter. Finally, Voya Investment Management LLC lifted its position in Bio-Rad Laboratories by 7.1% in the 1st quarter. Voya Investment Management LLC now owns 2,461 shares of the medical research company’s stock valued at $599,000 after acquiring an additional 164 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wells Fargo & Company increased their price target on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Citigroup raised their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Trading Down 0.1%

NYSE BIO opened at $312.50 on Thursday. The business’s fifty day moving average is $312.96 and its 200-day moving average is $296.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.44 and a quick ratio of 3.94. The stock has a market capitalization of $8.43 billion, a price-to-earnings ratio of -12.85 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $373.69.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million for the quarter, compared to analysts’ expectations of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.The business’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Insider Activity at Bio-Rad Laboratories

In related news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the sale, the executive vice president owned 510 shares of the company’s stock, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.